2024-03-29T14:31:23Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/2178472020-12-10T08:44:57Zcom_10261_5062com_10261_5col_10261_5064
2020-08-12T10:55:05Z
urn:hdl:10261/217847
Effect of probiotics on symptoms of irritable bowel syndrome: A meta-analysis updated | Efecto de los probióticos en los síntomas del síndrome del intestino irritable: Un meta-análisis actualizado
Ortiz-Lucas, M.
Tobías, Aurelio
Saz, P.
Sebastián, J.J.
Background and objectives: immune system alteration in irritable bowel syndrome (IBS) patients may be modulated by probiotics. We assessed the efficacy of some probiotic species in alleviating characteristic IBS symptoms. Material and methods: a meta-analysis of all identified randomized controlled trials comparing probiotics with placebo in treating IBS symptoms was performed with continuous data summarized using standardized mean differences (SMDs) with 95% confidence intervals (95% CIs), where appropriate. The randomeffects model was employed in cases of heterogeneity; otherwise, fixed-effects models were used. Results: meta-analysis was performed with 10 of 24 studies identified as suitable for inclusion. Probiotics improved pain scores if they contained Bifidobacterium breve (SMD, -0.34; 95% CI, -0.66; -0.02), Bifidobacterium longum (SMD, -0.48; 95% CI, -0.91; -0.06), or Lactobacillus acidophilus (SMD, -0.31; 95% CI, -0.61; -0.01) species. Distension scores were improved by probiotics containing B. breve (SMD, -0.45; 95% CI, -0.77; -0.13), Bifidobacterium infantis, Lactobacillus casei, or Lactobacillus plantarum(SMD, -0.53; 95% CI, -1.00; -0.06) species. All probiotic species tested improved flatulence: B. breve (SMD, -0.42; 95% CI, -0.75; -0.10), B. infantis, L. casei, L. plantarum(SMD, -0.60; 95% CI, -1.07; -0.13), B. longum, L. acidophilus, Lactobacillus bulgaricus, and Streptococcus salivarius ssp. thermophilus (SMD, -0.61; 95% CI, -1.01; -0.21). There was not a clear positive effect of probiotics concerning the quality of life. Conclusions: some probiotics are an effective therapeutic option for IBS patients, and the effects on each IBS symptom are likely species-specific. Future studies must focus on the role of probiotics in modulating intestinal microbiota and the immune system while considering individual patient symptom profiles. © 2013 ARÁN EDICIONES, S. L.
2020-08-12T10:55:05Z
2020-08-12T10:55:05Z
2013
2020-08-12T10:55:06Z
artículo
Revista Espanola de Enfermedades Digestivas 105: 19- 36 (2013)
http://hdl.handle.net/10261/217847
Publisher's version
http://dx.doi.org/null
Sí
openAccess
Aran Ediciones